



RareVision

Turning DNA data
into action with
whole genome insights


INOCRAS

FIND ANSWERS – FASTER

Identifying your risk can change your future

Almost 40% of rare disease patients¹ received a misdiagnosis in their journey. This delays your ability to start effective treatments for rare disease symptoms that may get worse over time.

RareVision equips you with more information about what might be causing your or your child's symptoms, helping narrow down your diagnosis and may lead to a quicker, more accurate diagnosis.



We look at the whole picture of your genomic blueprint, not just a small part of it. This allows us to find not only simple changes to your DNA, but complicated ones too. When we see more, we get more insights.

Looking at a much smaller portion of your genetic blueprint could mean missing key changes to your DNA, which could lead to a delayed or missed diagnosis.



RareVision

Take control of your health to take control of your future

Get the whole picture of your genetic health and more insights about your genes that could contribute to rare diseases, all within two weeks.*

- **Whole genome sequencing** that looks at your genes to assess your risk of rare disease
- **Personalized support from a genetic counselor** to help you understand the test findings and answer your questions
- **Actionable insights** to help you take control of your health
- **2 week turnaround time***

Price: \$2,400[†]

*2 weeks from receipt of your blood samples at our lab.

[†]The listed price is a general estimate. The price may vary depending on your country and the specific scope of services we provide tailored to your needs.

DID YOU KNOW?

It can take an average of 4-5 years² to get a diagnosis of a rare disease. Our whole genome test looks at the bigger picture of your genes for a more holistic understanding of how rare disease could affect your health, so you get the answers you need – faster.



¹ https://rarediseases.org/wp-content/uploads/2022/10/NRD-2088-Barriers-30-Yr-Survey-Report_FNL-2.pdf

² Willmen T, Willmen L, Pankow A, Ronicke S, Gabriel H, Wagner AD. Rare diseases: why is a rapid referral to an expert center so important? BMC Health Serv Res. 2023 Aug 23;23(1):904. doi: 10.1186/s12913-023-09886-7. PMID: 37612679; PMCID: PMC10463573.

STORIES WITH IMPACT

Andrew's story

Andrew, a 1-year-old boy, was experiencing a myriad of perplexing symptoms, including decreased muscle tone, facial abnormalities, and developmental delays. With the hope of finding answers, Andrew's provider ordered the RareVision test. The results revealed a change to his DNA that supported a definitive diagnosis of a rare genetic disorder called Noonan syndrome.

This finding provided a roadmap for his future care that allowed his family to take proactive steps in managing his health and to make empowered family planning decisions.

Chloe's story

Chloe, 17, had severe symptoms that affected her intestines. Doctors suspected inflammatory bowel disease (IBD), but finding the exact cause remained a challenge.

Her results from RareVision revealed two disease-causing changes to her DNA that confirmed her diagnosis of early-onset IBD. **She learned that IBD caused by her mutations can be treated, and even cured, through hematopoietic stem cell transplantation. She is now actively preparing for transplantation, a potential treatment for her condition.**

Request an order for RareVision

testing today at inocras.com

While all patient names provided are fictionalized to ensure privacy and confidentiality, the age, disease information, and diagnostic process in the testimonials are based on real cases. Please note that clinical outcomes may vary for each individual. These patient stories are based on collaborative research funded by Inocras.

How can I order RareVision?



Sign up

Fill out the online order request form and consent form at **inocras.com**.



Clinician approval

An external clinician will review and order your test request.



Blood sample collection

Once your test order is made, we'll send you a link to make an appointment with a phlebotomist, who will visit your home and draw your blood.



Genetic counselor appointment

When your report is ready, you will receive a notification with a link to make an appointment with a genetic counselor who will review your results with you.



Result review

A genetic counselor will review your RareVision report with you.



**Scan the QR
code to get
started**

RareVision

What you'll receive

An comprehensive, easy-to-understand testing report that provides an overview of your genetic risk for rare disease

Personalized support from a genetic counselor to help you understand your test findings and answer your questions

Actionable insights to help you take control of your health

Request an order
for **RareVision**
testing today

at **inocras.com**

RareVision

Patient
Name: John Smith
Patient ID: H23/028662
Sex at birth: Male
Date of birth: Nov 20, 1987

Physician
Name: John Doe
Institution:
Heritage Medical Center
Contact: +82-10-0000-0000
Address:
1600 Amphitheatre Parkway,
Mountain View, CA 94043

Specimen
Specimen ID: C346399(9)
Specimen type: Blood
Specimen collection:
Blood draw
Collected: Nov 20, 2023, 11:23
Received: Nov 24, 2023, 13:20
Clinical diagnosis:
Autism spectrum disorder

Test Information
Test name:
Whole genome analysis and
interpretation
Quality: Satisfactory
Sequencing mean depth:
48.2x

John Smith
Patient ID: H23/028662

RESULT SUMMARY

Positive variants detected	PTEN
Inconclusive variants detected	SCN2A, TCF7L2
Secondary (incidental) findings detected	BRCA1

A. POSITIVE VARIANTS

Gene	Variant type	Zygosity	ACMG classification	Related diseases
PTEN	SNV	Heterozygosity	Likely pathogenic	Lhermitte-Duclos disease

B. INCONCLUSIVE VARIANTS

Gene	Variant type	Zygosity	ACMG classification	Related diseases
SCN2A	SNV	Heterozygosity	Pathogenic	Developmental and epileptic encephalopathy 11
TCF7L2	SV	Heterozygosity	-	Diabetes mellitus, type 2, susceptibility to

C. SECONDARY (INCIDENTAL) FINDING

Gene	Variant type	Zygosity	ACMG classification	Related diseases
BRCA2	SNV	Heterozygosity	Likely pathogenic	Breast-ovarian cancer, familial, 2

D. INTERPRETATION

- In PTEN, variant ENSP00000278317.6:p.R234H is detected as likely pathogenic, and the variant is identified as heterozygous. And the variant is identified as de novo.
- PTEN is known to be associated with the following diseases.
Lhermitte-Duclos disease (Autosomal dominant) (PMID: 24102544, 21926107).
- Incidentally, in BRCA2, variant ENSP00000262426.4:p.F85L is detected as likely pathogenic, and the variant is identified as heterozygous. And the variant is identified as de novo.
- BRCA2 is known to be associated with the following diseases.
Breast-ovarian cancer, familial, 2 (Autosomal dominant) (PMID: 17924331).
- Geneticist evaluation for clinical correlation of these results is recommended.

*SNV: Single nucleotide variant; INDEL: Insertion and deletion; SV: Structural variation; TE: Transposable elements; DEL: Deletion; DUP: Duplication; INV: Inversion; BND: Translocation; Chr: Chromosome, AD: Autosomal dominant, AR: Autosomal recessive; XR, X-linked recessive

INOCRAS

Date: Nov 23, 2023
Signed By: Veena Singh, MD, FCAP, FACMG, Laboratory Director

Accession #: 23-1385
CLIA #: 05D2280195
Address: 6330 Nancy Ridge Drive, Suite 106, San Diego, CA 92121

Contact: (866)665-2120
1 / 9

INOCRAS

INOCRAS.COM

6330 Nancy Ridge Drive, Suite 106
San Diego, CA 92121

IP24-0524